Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Status
- RECRUITING
- Phase
- PHASE3
The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia
- Status
- RECRUITING
- Phase
- PHASE2
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Status
- RECRUITING
- Phase
- PHASE3
NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Status
- RECRUITING
- Phase
- PHASE3
Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
PVd Versus Vd in NDMM Patients With RI
- Status
- UNKNOWN
- Phase
- PHASE2
Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Bortezomib for Treating Glomerular Diseases
- Status
- UNKNOWN
- Phase
- NA
Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
- Status
- WITHDRAWN
- Phase
- PHASE2
Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT
- Status
- RECRUITING
- Phase
- N/A